Is Aligos Therapeutics, Inc. ALGS stock halal to invest in?

No, as of February 2026, Aligos Therapeutics, Inc. stock (ALGS) is currently categorized as NOT Shariah Compliant. The company's status is determined by a rigorous financial screening process, which uses the criteria set by the AAOIFI (Accounting and Auditing Organization for Islamic Financial Institutions) as the primary global standard for Islamic investing. Aligos Therapeutics, Inc. has been assessed to have exceeded the permissible financial thresholds—specifically in areas like interest-bearing debt or non-permissible income (such as income from interest)—and, therefore, does not qualify as a halal investment under the current review. For investors seeking Shariah compliant global stocks, it is essential to check the latest compliance status, as these screenings are updated regularly (e.g., monthly) or upon the release of new financial reports. You can find the most current status for Aligos Therapeutics, Inc. and alternative halal stock options within the Tabadulat app.

How often is Aligos Therapeutics, Inc. ALGS reviewed for Shariah compliance?

At Tabadulat, we receive Shariah compliance data on Aligos Therapeutics, Inc. ALGS monthly. We apply the rigorous AAOIFI screening methodology under the direct supervision of our dedicated Shariah Supervisory Board to ensure your investments are consistently compliant.

Does Aligos Therapeutics, Inc. ALGS pass the AAOIFI Non Permissible Income criteria?

No, as of February 2026, Aligos Therapeutics, Inc. stock (ALGS) does not pass the AAOIFI Non Permissible Income criterion. The company's income from non-permissible sources has exceeded the permissible threshold set by AAOIFI, indicating the stock is currently not Shariah compliant for this screen.

Does Aligos Therapeutics, Inc. ALGS pass the AAOIFI Interest Bearing Investments criteria?

No, as of February 2026, Aligos Therapeutics, Inc. stock (ALGS) does not pass the AAOIFI Interest Bearing Investments criterion. The company's interest-bearing investments have exceeded the permissible threshold set by AAOIFI, indicating the stock is currently not Shariah compliant for this screen.

Does STOCK pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of February 2026, Aligos Therapeutics, Inc. stock (ALGS) passes the AAOIFI Interest Bearing Debt criterion. The company's interest-bearing debt is below the acceptable threshold set by AAOIFI.

English

العربية

Be the First to Know!

Join our waitlist for exclusive early access to Tabadulat’s Shariah-compliant trading platform. Get notified as soon as we go live and start investing with confidence.

Aligos Therapeutics, Inc.

NASDAQ

Shariah-Compliant

Not Shariah

ALGS

About

Aligos Therapeutics, Inc.

ALGS

Aligos Therapeutics Inc. is a clinical-stage biotechnology company specializing in the discovery and development of targeted antiviral and liver disease therapies. The firm focuses on unmet medical needs in chronic liver and viral diseases, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and coronavirus infections. Its pipeline includes innovative oral small molecule drug candidates such as Pevifoscorvir sodium, a capsid assembly modulator targeting chronic hepatitis B virus infection, and ALG-055009, a thyroid hormone receptor beta agonist for metabolic dysfunction-associated steatohepatitis. Leveraging a science-driven approach and expertise in hepatology and virology, Aligos aims to develop best-in-class molecules with enhanced pharmacologic properties to improve patient outcomes. The company’s research collaborations and licensing agreements support its efforts to pioneer therapies addressing substantial global health burdens linked to liver disease and viral infections.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

Website:

https://www.aligos.com

ALGS

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Sign Up.

Begin by creating your Tabadulat account. Simply enter your details and complete the verification process. You’ll be up and running in no time.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.

Step 4

Trade.

Once you’ve chosen the right stocks, simply place your trades. Our platform offers real-time market data and seamless execution.

Mobile screen showing investment portfolio with $100,000 total value, $48,000 invested, and a $2,000 return (4.50%) with a line graph and options for 1W, 1M, 3M, YTD, 1Y, Max, plus Trade and Deposit buttons.

Step 5

Track.

Track your Portfolio and monitor your investments with our easy-to-use dashboard. View your portfolio performance, manage assets, and make adjustments as needed.

Step 6

Withdraw.

When you're ready, withdraw your funds quickly and securely to your bank account.

Aligos Therapeutics, Inc.

About

Aligos Therapeutics, Inc.

ALGS

Frequently asked questions

Is Aligos Therapeutics, Inc. ALGS stock halal to invest in?

How often is Aligos Therapeutics, Inc. ALGS reviewed for Shariah compliance?

Does Aligos Therapeutics, Inc. ALGS pass the AAOIFI Non Permissible Income criteria?

Does Aligos Therapeutics, Inc. ALGS pass the AAOIFI Interest Bearing Investments criteria?

Does STOCK pass the AAOIFI Interest Bearing Debt criteria?

How do I buy Aligos Therapeutics, Inc. ALGS stock?

Sign Up.

Deposit.

Screen.

Trade.

Track.

Withdraw.